PHARMCHEM LABORATORIES, INC. – Trademark Portfolio
Entity Type: 03
PHARMCHEM LABORATORIES, INC. has 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include PHARMCHEK. The portfolio includes 1 registered trademark. Filings span 4 Nice Classification classes, led by Class 42 (Computer & Scientific) and Class 1 (Chemicals). This trademark owner is based in MENLO PARK, CA.
3925 BOHANNON DRIVE
MENLO PARK, CA 94025
Showing of trademarks Trademarks
Trademark Classifications
PHARMCHEM LABORATORIES, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PHARMCHEM LABORATORIES, INC. have?
PHARMCHEM LABORATORIES, INC. has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 5 cancelled.
What trademark classes does PHARMCHEM LABORATORIES, INC. file in?
PHARMCHEM LABORATORIES, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are PHARMCHEM LABORATORIES, INC.'s most well-known trademarks?
PHARMCHEM LABORATORIES, INC.'s registered trademark portfolio includes well-known marks such as PHARMCHEK. These are among 1 currently registered trademark in the portfolio.
What is PHARMCHEM LABORATORIES, INC.'s trademark registration success rate?
PHARMCHEM LABORATORIES, INC. has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.